|FAM134B (E8Y9R) Rabbit mAb 83414||20 µl||
||H M R||70||Rabbit IgG|
|CCPG1 (E3C5G) Rabbit mAb 80158||20 µl||
|XBP-1s (E9V3E) Rabbit mAb 40435||20 µl||
||H M R||60 (human), 55 (mouse/rat)||Rabbit IgG|
|ATF-6 (D4Z8V) Rabbit mAb 65880||20 µl||
||H M||90-100||Rabbit IgG|
|Phospho-eIF2α (Ser51) (D9G8) XP® Rabbit mAb 3398||20 µl||
||H M R Mk Dm||38||Rabbit IgG|
|PERK (C33E10) Rabbit mAb 3192||20 µl||
||H M R Mk||140||Rabbit IgG|
|ATF-4 (D4B8) Rabbit mAb 11815||20 µl||
||H M R||49||Rabbit IgG|
|IRE1α (14C10) Rabbit mAb 3294||20 µl||
||H M R||130||Rabbit IgG|
|BiP (C50B12) Rabbit mAb 3177||20 µl||
||H M||78||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody 7074||100 µl||
Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding Pro327 of human FAM134B protein, Ala361 of mouse XBP-1s protein, Ala246 of human PERK protein, His963 of human IRE1α protein, Gly584 of human BiP protein, residues near the carboxy terminus of human ATF-6 and ATF-4 protein, and a synthetic phosphopeptide corresponding to residues surrounding Ser51 of human eIF2α protein.
The endoplasmic reticulum (ER) is a large organelle extending from the nuclear envelope to the plasma membrane with diversity in structure and function (1,2). It functions in calcium storage, lipid and steroid synthesis, and protein folding, processing, and transport. ER structure and function is regulated in a dynamic fashion adapting to situations of ER stress and organelle damage (1,2). When demands on protein processing exceeds capabilities, cells trigger an adaptive mechanism called the unfolded protein response (UPR) which is largely controlled by the activities of three pathways: PERK, IRE1α, and ATF-6 (1). The ER chaperone protein BiP is recruited to unfolded proteins in the ER lumen and its dissociation from PERK, IRE1α, and ATF-6 leads to their activation. PERK is a kinase on the ER membrane that couples ER stress to changes in translation. PERK activation during ER stress leads to phosphorylation of eIF2α, repressing most translation but selectively inducing some targets such as ATF-4, a transcription factor that regulates targets in the recovery of the stress response. IRE1α is an ER protein with endoribonuclease activity that is activated during ER stress and converts XBP-1 from an unspliced XBP-1μ isoform to a spliced XBP-1s isoform functioning as a transcription factor regulating stress response genes. Lastly, during ER stress, ATF-6 is cleaved liberating a mature transcription factor controlling stress response genes.
Subsequent to ER expansion triggered by the UPR, cells may trigger a process of ER-phagy, the degradation of ER fragments through autophagy (3). Autophagy is a process for the bulk degradation of cytoplasmic components by a double membrane autophagosome fusing to the lysosome. Selective autophagy, like ER-phagy, permits the degradation of specific targets. This process generally involves specific cargo receptors containing LIR or GIM domains targeting bound cargo to the autophagosome through interactions with LC3 or GABARAP, respectively. FAM134B was the first ER-phagy receptor discovered. Loss of FAM134B can sensitize cells to apoptosis when challenged by nutrient deprivation or ER stress stimuli. CCPG1 is another ER-phagy cargo receptor that associates with FIP200, a component of the ULK1 complex facilitating ER trafficking to autophagosomes. Importantly, CCPG1 is transcriptionally regulated by ER stress. Taken together, signaling from the UPR and ER-phagy help regulate ER homeostasis. Defects in this process may contribute to pathological conditions, including metabolic and neurological disorders, cancer, and defense against infectious diseases (3).
Explore pathways related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.